{"paper_id": "dcf5ceaa5b1073dc28b8c9d965b6705ee634e2a0", "metadata": {"title": "Supplementary appendix", "authors": []}, "abstract": [], "body_text": [{"text": "(WHO) (2) , which has been updated in response to COVID-19. All patients were hospitalized in an isolation room according to French policy for suspected or confirmed cases.", "cite_spans": [{"start": 6, "end": 9, "text": "(2)", "ref_id": "BIBREF1"}], "ref_spans": [], "section": ""}, {"text": "Epidemiological data were collected onto standardized forms through interviews of infected persons, and contacts and relatives when possible, that were conducted by physicians from Regional Health Agencies and the National Public Health Agency (Sant\u00e9 Publique France). We collected information on the dates of contact at risk, date of illness onset and details on travels in France.", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "The illness severity was defined, according to WHO criteria for severe pneumonia in adults (WHO/nCoV/Clinical/2020.2 (3)) as fever or suspected respiratory infection, plus one of the following: respiratory rate >30 breaths/min, severe respiratory distress, or SpO2 <90% on room air). The Acute Respiratory Distress Syndrome was defined, according to WHO criteria : (1) new or worsening respiratory symptoms within one week of known clinical insult; (2) bilateral opacities, not fully explained by effusions, lobar or lung collapse, or nodules;", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "(3) respiratory failure not fully explained by cardiac failure or fluid overload; (4) 200 mmHg < PaO2/FiO2 \u2264 300 mmHg (with PEEP or CPAP \u22655 cmH2O,7 or non-ventilated).", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "RNA extraction was performed with the Extraction NucleoSpin Dx Virus kit (Macherey Nagel), or by the automated NucliSENS\u00ae easyMAG\u00ae (BioM\u00e9rieux, Marcy l'Etoile, France) using manufacturer's instructions. For", "cite_spans": [], "ref_spans": [], "section": "RNA extraction and real-time RT-PCR"}, {"text": "RdRp-IP1 RT-PCR (Table S1) , used for detection, RNA was extracted from 100 \u00b5l of specimen or culture supernatant and eluted in 100 \u00b5l of water and used as a template for real-time (rt) RT-PCR. A 25 \u03bcL reaction contained 5 \u03bcL of RNA, 12.5 \u03bcL of 2X reaction buffer provided with the Superscript III one step RT-PCR system with Platinum Taq Polymerase (Invitrogen, Darmstadt, Germany; containing 0.4 mM of each dNTPs and 3 mM magnesium sulfate), 1 \u03bcL of reverse transcriptase/ Taq mixture from the kit, 0.4 \u03bcL of a 50 mM magnesium sulfate solution (Invitrogen). Thermal cycling was performed at 55\u00b0C for 20 min for reverse transcription, followed by 95\u00b0C for 3 min and then 50 cycles of 95\u00b0C for 15 s, 58\u00b0C for 30 s, on a Light Cycler 480 (96) thermocycler (Roche) or on the QuantStudio5 rtPCR Systems (Thermo Fisher Scientific). For RdRp quantitative RT-PCR, RNA extraction was performed on the EMAG\u00ae platform (Biomerieux, Marcy-l'\u00c9toile, France), using manufacturer's instructions. RNA was extracted from 200 \u00b5l of sample eluted in 50 \u00b5l of elution buffer. The RdRp gene RT-PCR corresponds to the Charit\u00e9 protocol (4) using primers RdRP_SARSr-F2 and -R1 and the RdRP_SARSr-P2 (Table   S1 ). Amplification was performed using QuantStudio 5 rtPCR Systems (Thermo Fisher Scientific, Waltham, Massachusetts, USA).", "cite_spans": [], "ref_spans": [{"start": 16, "end": 26, "text": "(Table S1)", "ref_id": null}, {"start": 1176, "end": 1187, "text": "(Table   S1", "ref_id": null}], "section": "RNA extraction and real-time RT-PCR"}, {"text": "When a sample (respiratory samples, plasma or stool) was positive with RdRp-IP1, quantification of the number of RNA copies was done according to a scale ranging from 10 3 to 10 6 copies/\u00b5L. The viral load in stools was calculated as previously described (5) and expressed in number of RNA copies/g of stool. The quality of nasopharyngeal swabs was checked using the CELL Control r-gene\u00ae kit (BioM\u00e9rieux). This kit is provided with quantified plasmid for cellular quantification. All viral loads for respiratory samples were calculated as described above and normalized according the cellular quantification as the number of RNA copies/1 000 cells. All positive plasma samples were quantified and expressed as number of RNA copies/mL.", "cite_spans": [{"start": 255, "end": 258, "text": "(5)", "ref_id": "BIBREF4"}], "ref_spans": [], "section": "RNA extraction and real-time RT-PCR"}, {"text": "Primer and probe sequences (Eurogentec, Seraing, Belgium) are shown in Supplementary Table S1. They either correspond to the RdRp or E gene assay from the Charit\u00e9 protocol (4) or to the RdRp-IP1 assay designed at Institut Pasteur to target the RdRp gene spanning nt 12669-12759 (positions according SARS-CoV, NC_004718) based on the first sequences of SARS-CoV-2 made available on the GISAID database on January 11, 2020 (Supplementary Table S2 ).", "cite_spans": [{"start": 172, "end": 175, "text": "(4)", "ref_id": "BIBREF3"}], "ref_spans": [{"start": 421, "end": 444, "text": "(Supplementary Table S2", "ref_id": null}], "section": "Primers and probes"}, {"text": "RNA from specimens or from virus culture was extracted using the RNeasy mini kit (Qiagen, Courtaboeuf, France), and 100\u00b5l of sample mixed with 350\u00b5l RLT lysis buffer was incubated at 70\u00b0C for 5 minutes for virus inactivation. Extraction was performed according to the manufacturer's instructions and RNA was purified on SPRI beads RNA clean XP (Beckman Coulter, Brea, California, USA). cDNA was synthetized using the Maxima ", "cite_spans": [], "ref_spans": [], "section": "High Throughput virus sequencing"}, {"text": "All experiments were conducted under strict BSL3 conditions. Vero E6 cells (mycoplasma-free) seeded in 12well plates (4 \u00d7 10 5 cells/well) were cultured in DMEM (Thermo Fisher Scientific) containing 1% PS (Penicillin 10,000 U/mL; Streptomycin10,000 \u00b5g/mL) and supplemented with 5% FBS (Fetal Bovine Serum). Respiratory specimens were diluted 1:2 with DMEM 1% PS without FBS and supplemented with 1\u00b5g/ml TPCK-trypsin ", "cite_spans": [], "ref_spans": [], "section": "Virus isolation and virus titration"}, {"text": "Sequences PCR product size Ref.", "cite_spans": [], "ref_spans": [], "section": "Name"}, {"text": "NRCRV: National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France Table S2 -SARS-CoV-2 names and sequences", "cite_spans": [], "ref_spans": [{"start": 90, "end": 98, "text": "Table S2", "ref_id": null}], "section": "RdRp gene / Charit\u00e9"}, {"text": "We gratefully acknowledge the Authors, the Originating and Submitting Laboratories for their sequence and metadata shared through GISAID, on which this research is based. WARD  WARD  WARD  WARD  WARD/I  CU  ICU  ICU  ICU/  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD WARD WARD", "cite_spans": [], "ref_spans": [{"start": 171, "end": 287, "text": "WARD  WARD  WARD  WARD  WARD/I  CU  ICU  ICU  ICU/  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD", "ref_id": null}], "section": "RdRp gene / Charit\u00e9"}, {"text": "Any of the following symptoms", "cite_spans": [], "ref_spans": [], "section": "Symptoms"}, {"text": "White blood cell counts, 10 9 /L ICU  ICU  ICU  ICU  ICU  ICU/  WARD   WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD WARD WARD", "cite_spans": [], "ref_spans": [{"start": 33, "end": 153, "text": "ICU  ICU  ICU  ICU  ICU  ICU/  WARD   WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD", "ref_id": null}], "section": "Symptoms"}, {"text": "Any of the following symptoms ", "cite_spans": [], "ref_spans": [], "section": "Symptoms"}, {"text": "White blood cell counts, 10 9 /L 4 ND 5. WARD  WARD  /ICU   ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU ND  ND  ND  ND  21  21  18  17  23  21  19  16  14  20  21  22  22  18  22  23  Creatinine kinase, UI/L  ND  ND  ND  ND  47  47  34  38  39  82  84  157  294  294  561  558  474  329  251  448 Alanine WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  Symptoms Any of the following symptoms ND  38  ND  ND  36  ND  60  41  59  ND  21  31  ND  68  ND  ND  43  ND  ND  ND  C-reactive protein  ND  <5  ND  ND  <5  ND  <5  <5  <5  ND  <5  <5  ND  <5  ND  ND  <5  ND  ND  ND  Lactate UI/L  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND Cough", "cite_spans": [], "ref_spans": [{"start": 41, "end": 148, "text": "WARD  WARD  /ICU   ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU  ICU", "ref_id": null}, {"start": 149, "end": 341, "text": "ND  ND  ND  ND  21  21  18  17  23  21  19  16  14  20  21  22  22  18  22  23  Creatinine kinase, UI/L  ND  ND  ND  ND  47  47  34  38  39  82  84  157  294  294  561  558  474  329  251  448", "ref_id": null}, {"start": 350, "end": 448, "text": "WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  WARD  Symptoms", "ref_id": null}, {"start": 479, "end": 747, "text": "ND  38  ND  ND  36  ND  60  41  59  ND  21  31  ND  68  ND  ND  43  ND  ND  ND  C-reactive protein  ND  <5  ND  ND  <5  ND  <5  <5  <5  ND  <5  <5  ND  <5  ND  ND  <5  ND  ND  ND  Lactate UI/L  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND  ND", "ref_id": null}], "section": "Biological variables"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "<em>Severe acute respiratory syndrome-related coronavirus</em> -The species and its viruses, a statement of the Coronavirus Study Group", "authors": [{"first": "A", "middle": ["E"], "last": "Gorbalenya", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Open source clinical science for emerging infections", "authors": [{"first": "J", "middle": ["W"], "last": "Dunning", "suffix": ""}, {"first": "L", "middle": [], "last": "Merson", "suffix": ""}, {"first": "Ggu", "middle": [], "last": "Rohde", "suffix": ""}, {"first": "Z", "middle": [], "last": "Gao", "suffix": ""}, {"first": "M", "middle": ["G"], "last": "Semple", "suffix": ""}, {"first": "D", "middle": [], "last": "Tran", "suffix": ""}], "year": 2014, "venue": "Lancet Infect Dis", "volume": "14", "issn": "1", "pages": "8--9", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim guidance WHO/nCoV/Clinical/2020.2. WHO: WHO", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR", "authors": [{"first": "V", "middle": ["M"], "last": "Corman", "suffix": ""}, {"first": "O", "middle": [], "last": "Landt", "suffix": ""}, {"first": "M", "middle": [], "last": "Kaiser", "suffix": ""}, {"first": "R", "middle": [], "last": "Molenkamp", "suffix": ""}, {"first": "A", "middle": [], "last": "Meijer", "suffix": ""}, {"first": "D", "middle": ["K"], "last": "Chu", "suffix": ""}], "year": 2020, "venue": "Euro Surveill", "volume": "25", "issn": "3", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Evaluation of a New Device for Simplifying and Standardizing Stool Sample Preparation for Viral Molecular Testing with Limited Hands-On Time", "authors": [{"first": "L", "middle": [], "last": "Feghoul", "suffix": ""}, {"first": "M", "middle": [], "last": "Salmona", "suffix": ""}, {"first": "J", "middle": [], "last": "Cherot", "suffix": ""}, {"first": "M", "middle": [], "last": "Fahd", "suffix": ""}, {"first": "J", "middle": ["H"], "last": "Dalle", "suffix": ""}, {"first": "C", "middle": [], "last": "Vachon", "suffix": ""}], "year": 2016, "venue": "J Clin Microbiol", "volume": "54", "issn": "4", "pages": "928--961", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "New low-viscosity overlay medium for viral plaque assays", "authors": [{"first": "M", "middle": [], "last": "Matrosovich", "suffix": ""}, {"first": "T", "middle": [], "last": "Matrosovich", "suffix": ""}, {"first": "W", "middle": [], "last": "Garten", "suffix": ""}, {"first": "H", "middle": ["D"], "last": "Klenk", "suffix": ""}], "year": 2006, "venue": "Virol J", "volume": "3", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Methods ----------------------------------------------------------------------------------------------------------------1 Table S1 -RT-PCR for the detection of SARS-CoV-2: primers and probes used ---------------------------------------4Table S2-SARS-CoV-2 names and sequences ----------------------------------------------------------------------------------5TableS3-1 -Case #1 -Baseline characteristics and their changes over time ------------------------------------------7 Table S3-2 -Case #2 -Baseline characteristics and their changes over time ------------------------------------------8 Table S3-3 -Case #3 -Baseline characteristics and their changes over time ------------------------------------------9 Table S3-4 -Case #4 -Baseline characteristics and their changes over time ----------------------------------------10 Table S3-5 -Case #5 -Baseline characteristics and their changes over time ----------------------------------------11 Supplementary Fig. 1 -Case #1 -chest X-rays and lung CT-scan from the day after the diagnosis day (illness day 8) -----------------------------------------------------------------------------------------------------------------------------6", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer's instructions and purified again on SPRI beads RNA clean XP. Purified cDNA was sequenced on the P2M platform at Institut Pasteur. In brief, Nextera XT DNA Library Preparation\u00ae kit (Illumina, San Diego, California, USA) was used for library construction. The pooled libraries were sequenced on an Illumina NextSeq 500\u00ae instrument using a paired-end 150 bp run. The fastq files were generated and de-multiplexed with the bcl2fastq Conversion Software\u00ae v2.20 (Illumina). Data analyses were performed with CLC Genomics Workbench\u00ae 20. Consensus sequences were deposited in the GISAID database (https://www.gisaid.org/).", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Sigma-Aldrich, St Louis, Missouri, USA), added to the cells and incubated for one hour at 37\u00b0C in the presence of 5% CO2. The inoculum was then removed and replaced with fresh DMEM 1% PS containing 1\u00b5g/mL TPCKtrypsin. After incubation for three days at 37\u00b0C in the presence of 5% CO2, cells were observed for the presence of a cytopathic effect (CPE) under the microscope and culture supernatants were harvested, aliquoted and stored at -80\u00b0C. Virus titration was performed on Vero E6 cells in a standard plaque assay adapted from Matrosovich et al (6).", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Zhang,Y.-Z., Wu,F., Chen,Y.-M., Pei,Y.-Y., Xu,L., Wang,W., Zhao,S., Yu,B., Hu,Y., Tao,Z.-W., Song,Z.-G., Tian,J.-H., Zhang,Y.-L., Liu,Y., Zheng,J.-J., Dai,F.-H., Wang,Q.-M., She,J.-L. and Zhu,T.-Y.", "latex": null, "type": "figure"}, "TABREF0": {"text": "Weimin Zhou, Peihua Niu, Peipei Liu, Faxian Zhan, Weifeng Shi\uff0cBaoying Huang, Jun Liu, Li Zhao, Yao Meng\uff0cXiaozhou He, Fei Ye, Na Zhu, Yang Li, Jing Chen\uff0cWenbo Xu, George F. Gao, Guizhen Wu Lili Ren, Jianwei Wang, Qi Jin, Zichun Xiang, Zhiqiang Wu, Chao Wu, Yiwei Liu Peng Zhou, Xing-Lou Yang, Ding-Yu Zhang, Lei Zhang, Yan Zhu, Hao-Rui Si,", "latex": null, "type": "table"}, "TABREF1": {"text": "", "latex": null, "type": "table"}, "TABREF3": {"text": "2 -Case #2 -Baseline characteristics and their changes over time", "latex": null, "type": "table"}, "TABREF5": {"text": "Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Remdesivir D1", "latex": null, "type": "table"}, "TABREF6": {"text": "ICU", "latex": null, "type": "table"}, "TABREF7": {"text": "ND = not determined; NA = not applicable; ARDS = acute respiratory distress syndrome", "latex": null, "type": "table"}, "TABREF8": {"text": "4 -Case #4 -Baseline characteristics and their changes over time February 3 February 4 February 5 February 6 February 7 February 8 February 9 February 10 February 11 February 12Discharge day", "latex": null, "type": "table"}, "TABREF11": {"text": "Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air Ambient air ND = not determined; NA = not applicable", "latex": null, "type": "table"}}, "back_matter": [{"text": "White blood cell counts, 10 9 /L ND ND 3. ", "cite_spans": [], "ref_spans": [], "section": "Biological variables"}]}